Long-term Prognostic Significance of Pentraxin-3 in Patients with Non-ST Elevation Myocardial Infarction and Coronary Stenting

Basit Öğe Kaydı
dc.authoridKIRILMAZ, BAHADIR/0000-0002-5929-1426
dc.authoridKUCUK, UGUR/0000-0003-4669-7387
dc.contributor.authorKucuk, Ugur
dc.contributor.authorKirilmaz, Bahadir
dc.contributor.authorErcan, Ertugrul
dc.date.accessioned2025-01-27T20:24:19Z
dc.date.available2025-01-27T20:24:19Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAim: We aimed to investigate the relationship of serially measured pentraxin-3 (PTX3) levels with Gensini risk score and cardiovascular mortality in long-term follow-up in patients who underwent percutaneous coronary intervention (PCI) with the diagnosis of non -ST elevation myocardial infarction (NSTEMI) and stable angina pectoris (SAP). Materials and Methods: Our study was planned retrospectively, and the long-term cardiovascular mortality results of patients with NSTEMI and SAP, who underwent PCI, were evaluated. Our study consisted of two groups, including the study and the control groups. Eighteen patients with NSTEMI who underwent PCI were included in the study group, and 37 patients with a diagnosis of SAP were included in the control group. Blood samples were taken from all patients for PTX3 measurements at the time of admission, at the 8th and 24th hours. Gensini scores were calculated before PCI. Results: PTX3 levels measured at the eighth hour were found to be numerically and statistically significant in NSTEMI patients compared to SAP patients [13.37 (5.47-27.75) and 5 (3.83-12.42), p=0.006]. PTX3 values measured at the time of admission were found to be associated with Gensini score (r=0.299, p=0.026). PTX3 values measured at the eighth hour were found to be independent predictors of long-term cardiovascular mortality (Hazard ratio: 1.294, 95% confidence interval: 1024-1.653, p=0.039). Conclusion: PTX3 may be helpful in identifying individuals at high risk for cardiovascular mortality in the long term in NSTEMI patients.
dc.identifier.doi10.4274/nkmj.galenos.2022.86548
dc.identifier.endpage180
dc.identifier.issn2587-0262
dc.identifier.issue2
dc.identifier.startpage175
dc.identifier.trdizinid1129282
dc.identifier.urihttps://doi.org/10.4274/nkmj.galenos.2022.86548
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1129282
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22158
dc.identifier.volume10
dc.identifier.wosWOS:001207572200006
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherGalenos Publ House
dc.relation.ispartofNamik Kemal Medical Journal
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectAcute coronary syndrome
dc.subjectGensini risk score
dc.subjectpentraxin-3
dc.subjectlong-term prognosis
dc.titleLong-term Prognostic Significance of Pentraxin-3 in Patients with Non-ST Elevation Myocardial Infarction and Coronary Stenting
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu